cancer

Merck teams up with cancer startup Foghorn in $425M deal
Merck teams up with cancer startup Foghorn in $425M deal
Fierce Biotech
Merck
Foghorn Therapeutics
cancer
drug development
Flag link:
AI startup Nucleai has immuno-oncology treatment failures in its sights
AI startup Nucleai has immuno-oncology treatment failures in its sights
Pharmaforum
Nucleai
artificial intelligence
cancer
Debiopharm
immuno-oncology
Flag link:
Relay Lays $200M IPO Plan to Fund Tests of Protein Motion Cancer Drugs
Relay Lays $200M IPO Plan to Fund Tests of Protein Motion Cancer Drugs
Xconomy
Relay Therapeutics
IPOs
protein motion
cancer
Flag link:
Bayer Settles Roundup Lawsuit for Almost $11 Billion
Bayer Settles Roundup Lawsuit for Almost $11 Billion
Motley Fool
Bayer
Roundup
cancer
Flag link:
AstraZeneca first to join FDA's push for patient-reported symptoms in cancer trials
AstraZeneca first to join FDA's push for patient-reported symptoms in cancer trials
Fierce Pharma
AstraZeneca
patients
clinical trials
FDA
cancer
Flag link:
After filing for IPO, ArcherDX agrees to $1.4B buyout by Invitae
After filing for IPO, ArcherDX agrees to $1.4B buyout by Invitae
MedCity News
ArcherDX
M&A
IPOs
cancer
Invitae
Flag link:
Sanofi's fight for a better research reputation
Sanofi's fight for a better research reputation
BioPharma Dive
Sanofi
R&D
cancer
immune disorders
Flag link:
Merck KGaA’s ATR cancer drug cleared for further trials after phase 1 trial success
Merck KGaA’s ATR cancer drug cleared for further trials after phase 1 trial success
Pharmaforum
Merck KGaA
cancer
clinical trials
DNA repair
Flag link:
Jazz preps first solid tumor launch with Zepzelca's small cell lung cancer nod
Jazz preps first solid tumor launch with Zepzelca's small cell lung cancer nod
Fierce Pharma
Jazz Pharmaceuticals
solid tumors
cancer
Zepzelca
drug launches
Flag link:
Frazier Launches Lassen to Advance Antibodies Against Fibrosis, Cancer
Frazier Launches Lassen to Advance Antibodies Against Fibrosis, Cancer
Xconomy
Lassen Therapeutics
fibrosis
cancer
Flag link:
Merck eats the lunch Bristol Myers never served, winning TMB-based OK for Keytruda
Merck eats the lunch Bristol Myers never served, winning TMB-based OK for Keytruda
Endpoints
Merck
Keytruda
Bristol-Myers Squibb
FDA
biomarkers
accelerated approvals
cancer
TMB
Flag link:
GlaxoSmithKline pens $120M upfront synthetic lethality cancer pact with Ideaya
GlaxoSmithKline pens $120M upfront synthetic lethality cancer pact with Ideaya
Fierce Biotech
GSK
cancer
R&D
oncology
Ideaya
genome editing
Flag link:
AbbVie to pay Genmab $750M upfront to form bispecific R&D pact
AbbVie to pay Genmab $750M upfront to form bispecific R&D pact
Fierce Biotech
AbbVie
bispecific antibodies
cancer
Genmab
Regeneron
epcoritamab
Flag link:
Eight Fraudulent Cancer Research Studies Contained The Same Copied Results. How Does This Happen?
Eight Fraudulent Cancer Research Studies Contained The Same Copied Results. How Does This Happen?
Forbes
cancer
oncology
academic research
research fraud
Flag link:
Fresh off ASCO myeloma data, Legend Bio gets $424M in biotech's biggest IPO of 2020
Fresh off ASCO myeloma data, Legend Bio gets $424M in biotech's biggest IPO of 2020
BioPharma Dive
Legend Biotech
IPOs
cancer
cell therapies
ASCO 2020
Flag link:
Cullinan Oncology Reels In $98M to Advance Cancer Drug Pipeline
Cullinan Oncology Reels In $98M to Advance Cancer Drug Pipeline
Xconomy
Cullinan Oncology
cancer
oncology
Flag link:
ASCO 2020 round-up: Virtual conference still delivers the drama ASCO 2020 round-up: Virtual conference still delivers the drama
ASCO 2020 round-up: Virtual conference still delivers the drama ASCO 2020 round-up: Virtual conference still delivers the drama
Pharmaforum
ASCO 2020
Amgen
AstraZeneca
Bristol-Myers Squibb
cancer
CAR-T
COVID-19
Keytruda
Kyprolis
Tagrisso
Flag link:
AstraZeneca puts $55M into Accent as pharmas continue push to drug RNA
AstraZeneca puts $55M into Accent as pharmas continue push to drug RNA
BioPharma Dive
AstraZeneca
Accent Therapeutics
cancer
RNA
Flag link:
COVID-19 could slow progress in reducing cancer death, NCI head warns
COVID-19 could slow progress in reducing cancer death, NCI head warns
Biopharma Dive
cancer
cancer deaths
COVID-19
NCI
pandemic
Flag link:
After Inking Bristol Myers Pact, Repare Therapeutics Sets Sights on IPO
After Inking Bristol Myers Pact, Repare Therapeutics Sets Sights on IPO
Xconomy
cancer
IPOs
Repare Therapeutics
Bristol-Myers Squibb
Flag link:

Pages